Antibody drug conjugate (ADC)

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar: Therapeutic antibody innovation

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

Webinar highlights innovation in therapeutic antibody discovery

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

#Antibody drug conjugate (ADC) #Big pharma #Drug development #Drug discovery #Heidelberg Pharma #Takeda #Therapeutic Antibodies

A global overview of therapeutic antibody development

DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More

#Business & Investment #Exclusive Content

Ki67 staining
#Antibody drug conjugate (ADC) #Biospecimen collection #Monoclonal antibodies #Oncology

Advancing cancer therapy with antibody-drug conjugates

Cathie Miller, PhD, Senior Director of Product Marketing at BioIVT, discusses biospecimens and analytical techniques supporting the rapid evolution of ADCs in oncology. Antibody-drug conjugates (ADCs) are making significant strides forward as targeted cancer therapies. By coupling the specificity of antibodies with the potency of cytotoxic drugs, ADCs aim to… Read More

#Cancer Research #Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Callio Therapeutics #Financing #Oncology #Start-ups

$187m supports a new generation of ADC therapies

Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round.   Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.  The newly formed company, with headquarters in Seattle and Singapore, intends to use the proceeds… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry. You will hear from Aron Knickerbocker, CEO of Aulos Bioscience, and Martin… Read More

Webinar date:
Sponsored by Bio-Rad
#Webinars

#Antibody drug conjugate (ADC) #Cancer therapeutics #Cancer treatment #Interview #Oncology

Reducing cancer side effects through targeted therapies

Harry Palmer, Royal Commission of 1851 Industrial Fellow and PhD at University of Strathclyde, shares with DDW’s Megan Thomas how antibody-drug conjugates (ADCs) are revolutionising cancer treatment by offering targeted therapies with improved efficacy and reduced side effects, while addressing challenges in their development and paving the way for future… Read More

#Cancer Research #Exclusive Content

#Antibody drug conjugate (ADC) #Bispecific Antibodies #Breast cancer #Oncology #Solid tumours

This week in drug discovery (20-24 January) 

News round-up for 20-24 January by DDW Senior Digital Content Editor Diana Spencer. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, there have been a number of breakthroughs in the treatment of solid tumours,… Read More

#News

Cancer cells
#Antibody drug conjugate (ADC) #AstraZeneca #Breast cancer #Daiichi Sankyo #FDA #Oncology

FDA approved ADC improves breast cancer survival by 37%

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.  The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of disease progression or… Read More

#News #Regulatory

#Antibody drug conjugate (ADC) #Cancer immunotherapy #Cancer vaccine #Cell therapy #Immunotherapy

New DDW Highlights podcast: 20 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early… Read More

#News

#Antibody drug conjugate (ADC) #Cancer immunotherapy #Cancer vaccine #Cell therapy #Immunotherapy

This week in drug discovery (13-17 January) 

News round-up for 13-17 January by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for… Read More

#News

Multiple myeloma
#Antibody drug conjugate (ADC) #Clinical trials #Heidelberg Pharma #Myeloma

Heidelberg Pharma progresses multiple myeloma ADC

Heidelberg Pharma is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Heidelberg uses the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Innovent #Lung cancer #Oncology #Roche #Small cell lung cancer

Roche pays $80 million for Innovent’s lung cancer ADC

Roche and Innovent Biologics have agreed a collaboration and exclusive license agreement to develop antibody drug conjugate (ADC) IBI3009 for advanced small cell lung cancer.  Under the agreement, the two parties will jointly focus on the early-stage development of the ADC candidate, after which Roche will take over full development.  … Read More

#Business & Investment #News

Antibody drug conjugate
#Allink Biotherapeutics #Antibody drug conjugate (ADC) #Bispecific Antibodies #Financing

Allink raises $42m for bispecific antibody and ADC pipeline

Biotechnology company Allink Biotherapeutics has successfully completed a $42 million Series A financing.   The financing round was led by Lanchi Ventures, with participation new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine Capital.  "Since our… Read More

#Business & Investment #News

#Adcendo #Antibody drug conjugate (ADC) #Financing #Fundraising

Adcendo raises $135 million to advance ADC pipeline

Biotech company Adcendo has announced the successful closing of an oversubscribed $135 million Series B financing round.   Proceeds from the fundraise will be used to accelerate the development of the company's ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programmes.  The financing round was… Read More

#Business & Investment #News